Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.
作者： M. Saves , G. Chene , P. Ducimetiere , C. Leport , G. Le Moal
DOI: 10.1086/375844
关键词:
摘要: The distribution of risk factors for cardiovascular disease in patients aged 35–44 years who were treated human immunodeficiency virus type 1 (HIV-1) infection was compared with that a population-based cohort. HIV-1-infected men protease inhibitor-containing regimen (n = 223), HIV-1-uninfected 527), characterized by lower prevalence hypertension, mean high-density lipoprotein cholesterol level, higher smoking, waist-to-hip ratio, and triglyceride level. No difference found total plasma or low-density levels, nor the diabetes. Similar trends observed among female subjects. predicted coronary heart greater (relative [RR], 1.20) women (RR, 1.59; P < 10 -6 both), estimated attributable risks due to smoking 65% 29% women, respectively. Because most people will ultimately need antiretroviral therapy, should be determined at initiation treatment, interventions considered all have them.
oup.com
oxfordjournals.org
paperity.org
jstor.org 参考文章(20)
Bruno Gallet, Marc Pulik, Philippe Genet, Pierre Chedin, Michel Hiltgen, Vascular complications associated with use of HIV protease inhibitors. The Lancet. ,vol. 351, pp. 1958- 1959 ,(1998) , 10.1016/S0140-6736(05)78643-8
Fabrice Bonnet, Marianne Sav??s, C??cile Droz, Evelyne Peuchant, Genevi??ve Ch??ne, Jacques Beylot, Philippe Morlat, Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. Journal of Acquired Immune Deficiency Syndromes. ,vol. 25, pp. 199- 200 ,(2000) , 10.1097/00042560-200010010-00017
Andrew Carr, Katherine Samaras, Anna Thorisdottir, Gilbert R Kaufmann, Donald J Chisholm, David A Cooper, Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study The Lancet. ,vol. 353, pp. 2093- 2099 ,(1999) , 10.1016/S0140-6736(98)08468-2
Samuel A. Bozzette, Christopher F. Ake, Henry K. Tam, Sophia W. Chang, Thomas A. Louis, Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. The New England Journal of Medicine. ,vol. 348, pp. 702- 710 ,(2003) , 10.1056/NEJMOA022048
A K Sullivan, M R Nelson, G J Moyle, A M Newell, M D Feher, B G Gazzard, Coronary artery disease occurring with protease inhibitor therapy. International Journal of Std & Aids. ,vol. 9, pp. 711- 712 ,(1998) , 10.1258/0956462981921251
Kathleen Mulligan, Carl Grunfeld, Viva W. Tai, Heather Algren, Miyin Pang, David N. Chernoff, Joan C. Lo, Morris Schambelan, Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. Journal of Acquired Immune Deficiency Syndromes. ,vol. 23, pp. 35- 43 ,(2000) , 10.1097/00126334-200001010-00005
Matthias Egger, Cornelia Junghans, Nina Friis-Møller, Jens D. Lundgren, Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS. ,vol. 15, ,(2001) , 10.1097/00002030-200100005-00023
Judith S. Currier, Cardiovascular risk associated with HIV therapy. Journal of Acquired Immune Deficiency Syndromes. ,vol. 31, ,(2002) , 10.1097/00126334-200209011-00004
Carl Grunfeld, Donald P. Kotler, Randa Hamadeh, Anita Tierney, Jack Wang, Richard N. Pierson, Hypertriglyceridemia in the acquired immunodeficiency syndrome. The American Journal of Medicine. ,vol. 86, pp. 27- 31 ,(1989) , 10.1016/0002-9343(89)90225-8
Keaven M. Anderson, Patricia M. Odell, Peter W.F. Wilson, William B. Kannel, Cardiovascular disease risk profiles American Heart Journal. ,vol. 121, pp. 293- 298 ,(1991) , 10.1016/0002-8703(91)90861-B